David M. Brown, M.D. : Keeping Aflibercept 8 mg Dosing Intervals in DME.

Published Date: 22 Jun 2023

According to an analysis of the phase 2/3 PHOTON trial, most DME patients who received the drug aflibercept 8 mg kept their dosing intervals at 12 or 16 weeks.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Enhanced access for patients with prostate cancer is provided by the new SPECT/CT technique, which demonstrates remarkable biomarker identification.

2.

Reducing social media to an hour a day boosts young people's self-image.

3.

Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.

4.

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.

5.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot